← Back to Search

Leukotriene Inhibitor

Zafirlukast for Ovarian Cancer

Phase 2
Recruiting
Led By Jeffrey Zwicker, MD
Research Sponsored by Beth Israel Deaconess Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Minimum age ≥ 18 years. Because no dosing or adverse event data are currently available on the use of zafirlukast in participants under 18 years of age with ovarian cancer, children are excluded from this study but will be eligible for future pediatric trials.
Participants must meet criteria for tumor marker-only relapse, defined as CA-125 more than twice the upper limit of normal (35 U/mL) in the setting of a normal baseline CA-125 levels or CA-125 greater than twice the nadir count on two successive measurements for CA-125 values that remain above baseline without measurable radiographic disease.
Must not have
Pregnant women are excluded from this study because zafirlukast is a class B agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with zafirlukast, breastfeeding should be discontinued if the mother is treated with zafirlukast.
Currently receiving anticoagulant therapy.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 84 days
Awards & highlights

Summary

This trial is testing Zafirlukast, an asthma medication, to see if it can help patients with relapsed ovarian cancer. The drug may reduce tumor activity and lower the risk of blood clots based on lab studies. Zafirlukast is commonly used to improve asthma control.

Who is the study for?
This trial is for adult women with a specific type of ovarian cancer that has relapsed, indicated only by tumor markers without visible disease. They must have finished initial chemotherapy and surgery successfully, be able to swallow pills, and use contraception if childbearing potential. Men and those with certain health conditions or on conflicting medications are excluded.
What is being tested?
The study tests Zafirlukast's effectiveness in preventing tumor activity in women whose ovarian cancer has returned but is only detectable through tumor markers rather than physical tumors. Participants will take Zafirlukast tablets to see if it can control the cancer's return.
What are the potential side effects?
Zafirlukast may cause allergic reactions in some people similar to other drugs they might be allergic to. It could also potentially affect fetal development; hence pregnant women cannot participate. Other side effects are not detailed here.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
My CA-125 levels have doubled without signs of cancer on scans.
Select...
I can swallow pills.
Select...
I am 18 years old or older.
Select...
I have been diagnosed with ovarian, fallopian tube, or peritoneal cancer.
Select...
My blood counts and kidney and liver functions are within normal ranges.
Select...
I can take care of myself but might not be able to do heavy physical work.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am not pregnant or breastfeeding.
Select...
I am currently on blood thinner medication.
Select...
I am not taking any drugs that affect CYP2C9 enzyme activity.
Select...
I do not have brain metastases.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~84 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 84 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
CA-125 Response Rate
Secondary study objectives
Plasma D-Dimer Response Rate

Trial Design

1Treatment groups
Experimental Treatment
Group I: ZafirlukastExperimental Treatment1 Intervention
Zafirlukast will be taken orally at a pre-determined dose 2x daily for 28 day cycle up to 1 year.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Zafirlukast
2007
Completed Phase 1
~50

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for ovarian cancer include platinum-based chemotherapy, which works by causing DNA damage that leads to cancer cell death, and targeted therapies like PARP inhibitors, which prevent cancer cells from repairing DNA damage. Bevacizumab, an angiogenesis inhibitor, blocks the blood supply to tumors, inhibiting their growth. Zafirlukast, a leukotriene receptor antagonist, is being studied for its potential to prevent tumor activity by blocking leukotriene pathways involved in inflammation and cancer progression. Understanding these mechanisms is crucial for ovarian cancer patients as it helps in selecting the most effective treatment based on the tumor's specific characteristics and resistance patterns.
The Role of Eicosanoids in Gynecological Malignancies.Leukotriene B4 receptor-2 promotes invasiveness and metastasis of ovarian cancer cells through signal transducer and activator of transcription 3 (STAT3)-dependent up-regulation of matrix metalloproteinase 2.Current status of bevacizumab in advanced ovarian cancer.

Find a Location

Who is running the clinical trial?

Beth Israel Deaconess Medical CenterLead Sponsor
852 Previous Clinical Trials
12,930,463 Total Patients Enrolled
13 Trials studying Ovarian Cancer
496 Patients Enrolled for Ovarian Cancer
Dana-Farber Cancer InstituteOTHER
1,103 Previous Clinical Trials
359,368 Total Patients Enrolled
41 Trials studying Ovarian Cancer
4,699 Patients Enrolled for Ovarian Cancer
National Institutes of Health (NIH)NIH
2,794 Previous Clinical Trials
8,140,223 Total Patients Enrolled
13 Trials studying Ovarian Cancer
932 Patients Enrolled for Ovarian Cancer

Media Library

Zafirlukast (Leukotriene Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04339140 — Phase 2
Ovarian Cancer Research Study Groups: Zafirlukast
Ovarian Cancer Clinical Trial 2023: Zafirlukast Highlights & Side Effects. Trial Name: NCT04339140 — Phase 2
Zafirlukast (Leukotriene Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04339140 — Phase 2
~6 spots leftby Oct 2025